NASDAQ · Biotechnology

IMNN (IMNN) Stock

$1.53 +0.00% NASDAQ: IMNN Healthcare

Valuation

MetricValue
Price$1.53
Market Cap$3.86M
P/E Ratio-0.31
P/B Ratio0.77
P/S Ratio0.00
EPS (TTM)$-6.83
52-Week High$13.17
52-Week Low$1.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-200.00%
ROA-116.67%
ROCE-214.29%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.27
Current Ratio2.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$0$0
Operating Profit$-21.0M$-25.0M$-21.0M$-19.0M$-15.0M
Net Profit$-21.0M$-36.0M$-20.0M$-19.0M$-14.0M
EPS$-748.77$-65.55$-28.14$-21.10$-6.83
Op Margin-4201.4%-4984.3%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$74.0M$44.0M$22.0M$10.0M$12.0M
Total Liabilities$18.0M$15.0M$9.0M$5.0M$5.0M
Cash$20.0M$11.0M$6.0M$6.0M$9.0M
Borrowings$7.0M$6.0M$2.0M$1.0M$1.0M

Latest News

Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response MT Newswires · Jul 21, 2026 IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer GlobeNewswire · Jul 21, 2026 Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients Benzinga · Jul 21, 2026 OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD Zacks Small Cap Research · Jul 9, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-23.0M$-19.0M$-19.0M$-14.0M
Investing Cash Flow$-30.0M$8.0M$11.0M$10.0M$-1.0M
Financing Cash Flow$2.0M$0$0$0$0
Net Cash Flow$8.0M$-8.0M$-12.0M$0$3.0M
Free Cash Flow$-17.0M$-23.0M$-19.0M$-19.0M$-14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-280.36%
Quick Ratio1.59
Interest Coverage—
Return 1Y-72.08%
Return 3Y-88.35%
Return 5Y-99.06%

Ownership

Insiders Held5.08%
Institutions Held11.99%
Institutions Float Held12.63%
Institutional HolderSharesReport Date
Armistice Capital, LLC348,3302026-03-31
Vanguard Capital Management LLC48,0562026-03-31
Riverview Capital Advisers, LLC34,3642026-03-31
Geode Capital Management, LLC33,2112026-03-31
Vanguard Fiduciary Trust Co13,2692026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AEONAEON Biopharma, Inc. $0.24 -5.50% -0.05 $2.80M 0.00%
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
CING $4.52 -2.59% -1.08 $25.34M 0.00%
CLRB $2.37 -2.07% -0.38 $7.57M 0.00%
COCP $0.92 +0.14% -1.46 $12.68M 0.00%

About IMNN

IMNN is led by CEO Stacy R. Lindborg, employs 25 people, headquartered in US, publicly traded since 1999.

IMNN stock trades at $1.53 with a market capitalization of $3.86M. The stock is valued at a price-to-earnings (P/E) ratio of -0.31, price-to-book of 0.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.51 and $13.17, and currently trades 88.4% below its 52-week high.

On profitability, IMNN generates a return on equity (ROE) of -200.00%, return on capital employed of -214.29%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides